ADAR1 Capital Management, LLC purchased $248,615 worth of shares at $4.97, marking the largest insider purchase in the company's history. This significant buyback comes as the stock has crashed over 50% from its 52-week high, potentially signaling a bottom for the biotech.
Price context
NXTC has experienced extreme volatility, surging 132.16% over the last 30 days before dropping 16.28% in the past five days. The stock is currently trading at $4.295, which is 72.71% below its 52-week high of $15.74.
Catalysts to watch
1) Analysts project a potential upside of 107.88% based on current price targets (Zacks, Nov 11, 2025). 2) The company is set to go public via a reverse merger with Avere to advance a long-acting psoriasis pill (BioPharma Dive, July 14, 2026). 3) The current insider purchase is the largest ever recorded for the company.
Risks
1) The stock is currently trading at a forward P/E of -1.25, indicating continued unprofitability. 2) The company is classified as risky by Simply Wall St. due to its unprofitable nature (Oct 18, 2025).
AI-generated context from public data. Not investment advice. Verify before trading.